Maintenance Therapy with Anlotinib for Advanced Non-Small-Cell Lung Cancer
Key Findings
Maintenance therapy with anlotinib after platinum-based chemotherapy showed a median progression-free survival of 5.95 months and a median overall survival of 18.60 months in patients with advanced non-small cell lung cancer.
Results
Out of 23 patients, 19 had stable disease, 1 had a partial response, and 3 had progressive disease. The objective response rate was 4.35%, and the disease control rate was 86.96%. The incidence of adverse events of grade ≥ 3 was 21.7%.
Conclusion
Anlotinib offers a new option for maintenance treatment in patients with locally advanced or metastatic NSCLC after standard first-line platinum-based chemotherapy.
